Azelis Closes Koda Acquisition

Azelis completed its acquisition of US-based Koda Distribution Group (KDG) on Dec. 17 following clearance from the regulatory authorities. The deal was announced in mid-October this year.

KDG is now Azelis Americas, led by CEO and President Frank Bergonzi, the former CEO of KDG. The company will continue to operate in the US and Canada using its existing business model and local brands.

Azelis CEO Dr Hans-Joachim Mueller explained that the primary reason behind KDG’s acquisition was the revenue synergies that exist between the two companies which Azelis intends to exploit. “Going forward we will be focusing on generating fast-paced organic growth by extending our offering to the specific markets we serve. Moreover, we also will selectively pursue acquisition opportunities to complement our portfolio,” Mueller said.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.